Although we have not entered into the research of DOTA-(2P-PEG4)2-based PSMA TRT (targeting radionuclide therapy), [177Lu]Lu-DOTA-(2P-PEG4)2 still shows high tumor accumulation after 48 h, showing great potential for therapeutic applications in PCa. The gene discussed is FOLH1; the disease is neoplasm.